5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA)
作者： Mark J McKeage , Lloyd R Kelland
DOI: 10.2165/00024669-200605030-00002
关键词: Cancer 、 Clinical trial 、 Paclitaxel 、 Taxane 、 Oncology 、 Phases of clinical research 、 Internal medicine 、 Pharmacology 、 Carboplatin 、 Chemotherapy 、 Medicine 、 Docetaxel
摘要: Currently, there is a great deal of interest in drugs that target tumor vasculature and their therapeutic potential combination regimens for the treatment cancer. This review focuses on one vascular disrupting agents, 5-6-dimethylxanthenone 4-acetic acid (DMXAA), rationale its with standard taxane-based chemotherapy. DMXAA taxanes have different mechanisms action and, combination, demonstrate at least additive activity against preclinical solid tumors. Their clinical adverse-effect pharmacologic profiles as single agents appear to render these suitable use combination. Phase I studies identified range doses trials. In addition, indications chemotherapy been selected from positive randomized controlled trials advanced cancers. A phase II program now underway; paclitaxel carboplatin patients NSCLC ovarian cancer docetaxel hormone-refractory prostate are being evaluated.
springer.com
sci-hub.se 参考文章(31)
Bronwyn G. Siim, Bruce C. Baguley, Flavones and Xanthenones as Vascular‐disrupting Agents John Wiley & Sons, Ltd. pp. 159- 178 ,(2006) , 10.1002/0470035439.CH9
R. B. Pedley, J. A. Boden, R. Boden, A. A. Flynn, P. A. Keep, R. H. J. Begent, G. M. Boxer, Ablation of Colorectal Xenografts with Combined Radioimmunotherapy and Tumor Blood Flow-modifying Agents Cancer Research. ,vol. 56, pp. 3293- 3300 ,(1996)
Diane Fairclough, David Cella, John Kugler, Eric Rowinsky, Michael Jiroutek, David Johnson, Philip Bonomi, KyungMann Kim, Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial Journal of Clinical Oncology. ,vol. 18, pp. 623- 631 ,(2000) , 10.1200/JCO.2000.18.3.623
Bruce C. Baguley, Wayne R. Joseph, Lai-Ming Ching, Elaine S. Marshall, Zhihui Cao, Kathleen G. Mountjoy, Stimulation of Tumors to Synthesize Tumor Necrosis Factor-α in Situ Using 5,6-Dimethylxanthenone-4-acetic Acid A Novel Approach to Cancer Therapy Cancer Research. ,vol. 59, pp. 633- 638 ,(1999)
Gillian M. Tozer, Chryso Kanthou, Bruce C. Baguley, Disrupting tumour blood vessels Nature Reviews Cancer. ,vol. 5, pp. 423- 435 ,(2005) , 10.1038/NRC1628
Lesley D. McPhail, Dominick J.O. McIntyre, Christian Ludwig, Philip Kestell, John R. Griffiths, Lloyd R. Kelland, Simon P. Robinson, Rat Tumor Response to the Vascular-Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid as Measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Plasma 5-Hydroxyindoleacetic Acid Levels, and Tumor Necrosis Neoplasia. ,vol. 8, pp. 199- 206 ,(2006) , 10.1593/NEO.05739
L. Zhao, S. Edgar, E. Marshall, L. Kelland, B. Baguley, 149 Inhibition of vasculogenic mimicry in melanoma by the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) Ejc Supplements. ,vol. 2, pp. 47- 48 ,(2004) , 10.1016/S1359-6349(04)80157-5
Liangli Zhao, Lai-Ming Ching, Philip Kestell, Lloyd R. Kelland, Bruce C. Baguley, Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability. International Journal of Cancer. ,vol. 116, pp. 322- 326 ,(2005) , 10.1002/IJC.21005
R. Murata, J. Overgaard, M. R. Horsman, Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. International Journal of Hyperthermia. ,vol. 17, pp. 508- 519 ,(2001) , 10.1080/02656730110087040